VistaGen Therapeutics Faces Class Action Lawsuit
Analysis based on 28 articles · First reported Jan 30, 2026 · Last updated Feb 26, 2026
The market is negatively impacted by the news of VistaGen Therapeutics' failed drug trial, leading to a significant drop in its stock price. The class action lawsuit filed by Pomerantz LLP further adds to the uncertainty and negative sentiment surrounding VistaGen Therapeutics.
Pomerantz LLP has filed a class action lawsuit against VistaGen Therapeutics, Inc. following the failure of its PALISADE-3 Phase 3 study for intranasal fasedienol, a treatment for social anxiety disorder. The study did not show statistically significant improvement on its primary or secondary endpoints, leading to an 80.25% decline in VistaGen Therapeutics' stock price on December 17, 2025. The lawsuit alleges securities fraud and other unlawful business practices by VistaGen Therapeutics and its officers/directors. Investors who purchased VistaGen Therapeutics securities during the Class Period have until March 16, 2026, to seek appointment as Lead Plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard